This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
AUA 2019
AUA 2019 Lower Urinary Tract Conditions
AUA 2019
Prostate Cancer
Bladder Cancer
Renal Cancer
Testis & Penile Cancers
Lower Urinary Tract Conditions
GU Reconstruction
Infections & Inflammation
Laparoscopic – Robotic Surgery
Sexual Function
Stone Disease
Press Releases
AUA 2019 Lower Urinary Tract Conditions
Viewing 101-120 of 11775 articles
IBCN 2024: Circulating Immune-Modulators of Response to Neoadjuvant Nivolumab + Nab-Paclitaxel in Muscle Invasive Bladder Cancer: Biomarker Analyses from Nure-COMBO Trial
IBCN 2024: Investigating BCG Induced B Cell Responses in Patients with Non-Muscle Invasive Bladder Cancer
IBCN 2024: Correlation of ctDNA Dynamics with Clinical Response in MIBC Patients Undergoing Trimodality Therapy
IBCN 2024: Dynamic Monitoring of Circulating Tumor DNA to Predict Prognosis in Muscle-Invasive Bladder Cancer Patients After Radical Cystectomy
IBCN 2024: Retifanlimab Monotherapy as Neoadjuvant Therapy for Patients with Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder: Results from the Multicenter OPTIMUS Umbrella Study
IBCN 2024: Undetectable ctDNA Status Before Radical Cystectomy Predicts Improved Outcomes
IBCN 2024: Keynote Lecture: Inferring Tumor Evolution from Single-Cell Data
IBCN 2024: Comprehensive Genomic Characterization of Early Stage Bladder Cancer
IBCN 2024: Elucidating the Response Rates to Additional BCG: Implications for Clinical Trial Design
ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Non-Prostate
ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate
ESMO 2024: Identification of Bladder Cancer Patients That Could Benefit from Early Post-Cystectomy Immunotherapy Based on Serial Circulating Tumour DNA Testing: Preliminary Results from the TOMBOLA Trial
ESMO 2024: Controversies in Testis Cancer: Escalation or De-escalation?
ESMO 2024: TAR-200 plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer Who Are Ineligible for or Refuse Neoadjuvant Cisplatin-Based Chemotherapy: Interim Analysis of SunRISe-4
ESMO 2024: Invited Discussant: JCOG1019, TOMBOLA, and SunRISe-4
ESMO 2024: Empowering Bladder Cancer Care Integrating Patient Preferences and Voices
ESMO 2024: Histology Subtypes (variants) of Bladder Cancer
ESMO 2024: JCOG1019 Phase III Study Comparing the Effectiveness of Watchful Waiting and Intravesical BCG in Patients with High-grade pT1 Bladder Cancer with pT0 on the 2nd Transurethral Resection Specimen
ESMO 2024: Nivolumab plus Chemoradiotherapy in Patients with Non-Metastatic Muscle-Invasive Bladder Cancer, Not Undergoing Cystectomy: A Phase II, Randomized Study by the Hellenic GU Cancer Group.
ESMO 2024: Health-Related Quality of Life from the CheckMate 901 Trial of Nivolumab as First-Line Therapy for Unresectable or Metastatic Urothelial Carcinoma
1
2
3
4
5
6
7
8
9
10
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
